IBRX vs TRV · rev $113.3M vs P/E 14, rev $48.83B
Immunitybio Inc (IBRX) versus The Travelers Companies Inc (TRV) — a side-by-side from cached financials, not a winner call.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
The Travelers Companies Inc (TRV) is a insurance - property & casualty company listed on US.
Latest reported IBRX revenue for 2025-12-31 was $113.3M. Net income was -$351.4M. Revenue was up 668.3% from 2024-12-31 to 2025-12-31. IBRX currently screens at market cap $7.88B.
Latest reported TRV revenue for 2025-12-31 was $48.83B. Net income was $6.29B. Revenue was up 5.2% from 2024-12-31 to 2025-12-31. TRV currently screens at market cap $59.84B and trailing P/E 14.4.
IBRX currently screens at market cap $7.88B. TRV currently screens at market cap $59.84B and trailing P/E 14.4.
Not investment advice. Open the IBRX and TRV stock pages for the full models.
Not investment advice.